Option chain shows key data for AlphaTime Acq's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for AlphaTime Acq.

AlphaTime Acq (NASDAQ:ATMC) Stock, Option Chain

AlphaTime Acquisition Corp is a blank check company in Cayman Islands. The company is incorporated of the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.

AlphaTime Acquisition Corp - Ordinary Shares

AlphaTime Acquisition Corp

AlphaTime Acquisition Corp - Right

Jefferies analyst Kaumil Gajrawala upgrades Freshpet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRPT#NASDAQ">FRPT</a>) from Hold to Buy and lowers the price target from $155 to $150.

News

Upgrades

Price Target

Analyst Ratings

FRPT

Jefferies Upgrades Freshpet to Buy, Lowers Price Target to $150

Cryptocurrency analyst James Van Straten shared his optimistic perspective on Bitcoin&#8217;s (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) ongoing market consolidation on Saturday, describing it as &#8220;bullish.&#8221;
What Happened: In an X post, Van Straten noted that, unlike the choppy period of 2024, Bitcoin&#8217;s price has consistently stayed above the Short-Term Holder Realized Price in the current cycle.
As the name suggests, the Short-Term Holder Realized Price is the average price at which short-term investors have purchased their Bitcoin. Historically, when Bitcoin&#8217;s price is above this level, it indicates a bullish market, as &#8220;weak hands,&#8221; known to have a low-risk tolerance, are in profit.
&#8220;Not all consolidations are the same. I've been beating the drum on how bullish this consolidation has been,&#8221; the analyst stated. &#8220;Investors are waiting and not chasing the price but I think impatience may prevail.&#8221;
The analyst went on to say that another dip would be &#8220;healthy&#8221; for the market.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Exactly! Not all consolidations are the same. I've been beating the drum on how bullish this consolidation has been. I've had one limit order filled since November. Investors are waiting and not chasing the price but I think impatience may prevail. Unlike 2024 chop period… <a href="https://t.co/mqfqrEMHcM">https://t.co/mqfqrEMHcM</a> <a href="https://t.co/Yf2YHAqUdJ">pic.twitter.com/Yf2YHAqUdJ</a>
&mdash; James Van Straten (@btcjvs) <a href="https://twitter.com/btcjvs/status/1893184115064627530?ref_src=twsrc%5Etfw">February 22, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Van Straten&#8217;s comments come amidst a challenging time for the crypto market, particularly for leading coins like&nbsp;Bitcoin&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BTC#NYSE">BTC</a>), which has been struggling to reclaim its $100,000 mark for the past three weeks.
See Also:<a href="https://www.benzinga.com/24/12/42735744/pharma-bro-martin-shkreli-predicts-doom-for-michael-saylors-microstrategy-as-stock-dips-below-300-in-after-hours-trading"> </a><a href="https://www.benzinga.com/general/entertainment/25/02/43905274/kanye-west-deletes-x-posts-on-potential-meme-coin-unfollows-changpeng-zhao-whats-he-upto">Kanye West Deletes X Posts On Potential Meme Coin, Unfollows Changpeng Zhao — What&#8217;s He Upto?</a>
Why It Matters: Van Straten&#8217;s comments come amid a challenging time for the cryptocurrency market, particularly for leading coins like Bitcoin, which has been <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43904736/bitcoin-dogecoin-struggle-ethereum-gains-amid-grim-crypto-sentiment-after-bybits-billion-dollar-hack-analyst-says-still-time-left-in-the-cycle">struggling to reclaim its $100,000 mark</a> for the past three weeks.
The rangebound action has impacted speculative interest for the leading coin, with Open Interest in Bitcoin futures falling 10% since the beginning of the month, <a href="https://www.coinglass.com/LiquidationData">according </a>to Coinglass. 
More than 50% of Bitcoin&#8217;s derivatives traders were positioned short as of this writing, suggesting a likelihood of another correction. 
The market has been grappling with the aftermath of a massive $1.4 billion hack on cryptocurrency exchange Bybit, which has significantly impacted leading coins.
Price Action: At the time of writing, Bitcoin was exchanging hands at $95,721.70, down 0.53% in the last 24 hours, according to <a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;380nj0&#x2A;_ga&#x2A;MTEyOTAyOTcxMy4xNzEzMzY0NTYy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDk4MzIzMi42LjEuMTcxNDk4OTE0Ni4wLjAuMA..">data from Benzinga Pro</a>.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/personal-finance/financial-advisors/25/02/43903229/advisors-remain-divided-on-crypto-but-sec-approvals-demand-are-shifting-views">Advisors Remain Divided On Crypto, But SEC Approvals, Demand Are Shifting Views</a></li>
</ul>
Image via Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

$BTC

Bitcoin Poised For Growth? Analyst Says 'One More Flush' Could Set Stage For Surge

Jefferies analyst Randal Konik upgrades Nike (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) from Hold to Buy and raises the price target from $75 to $115.

Jefferies Upgrades Nike to Buy, Raises Price Target to $115

Jefferies analyst Edison Lee downgrades GDS Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDS#NASDAQ">GDS</a>) from Buy to Hold and raises the price target from $27.06 to $45.

Downgrades

Jefferies Downgrades GDS Holdings to Hold, Raises Price Target to $45

Just Eat Takeaway.com N.V. (AMS: TKWY), hereinafter the "Company" or "Just Eat Takeaway.com", one of the world's leading on-demand delivery companies, and Prosus, the global technology company, are pleased to announce they have reached conditional agreement on an envisaged recommended public offer by Prosus for all issued and outstanding shares in the capital of Just Eat Takeaway.com (the "Shares", and each a "Share") of EUR 20.30 (cum dividend) in cash per Share (the "Consideration"). The Offer values a 100% of the Shares at approximately EUR 4.1 billion.

JTKWY

Earlier It Was Announced Prosus To Acquire Just Eat Takeaway.com For €4.1B In Cash

Sasol's financial performance for the six months ended 31&nbsp;December&nbsp;2024 was impacted by a challenging macroeconomic and operating environment. Stringent cost and efficient capital management helped to off-set the impact and improve free cash flow generation compared to the six months ended 31&nbsp;December&nbsp;2023 (the prior period).
Revenue of R122,1 billion is 10% lower than the prior period, mainly as a result of:
<ul>
<li>A 13% decline in the average Rand per barrel Brent crude oil price and a significant decline in refining margins and fuel price differentials; and</li>
<li>A 5% decrease in sales volumes as a result of lower production and lower market demand as detailed in the Production and Sales Metrics published on 23 January 2025.</li>
</ul>
Adjusted earnings before interest, tax, depreciation and amortisation (adjusted EBITDA) of R23,9&nbsp;billion is 15% lower compared to the prior period mainly as a result of the aforementioned lower revenue with stringent cost management implemented in response helping to mitigate the impact. The relative contribution from International Chemicals increased from 6% to 13%.
Earnings before interest and tax (EBIT) of R9,5 billion is 40% lower than the prior period and impacted by non-cash adjustments including:
<ul>
<li>A net loss of R6,2 billion from remeasurement items compared to a net loss of R5,8 billion in the prior period, mainly due to further impairments of the Secunda liquid fuels refinery cash generating unit (CGU) of R5,0 billion and the Sasolburg liquid fuels refinery CGU of R0,6 billion. Both CGUs remain fully impaired, resulting in amounts capitalised during the current period being impaired.</li>
<li>Unrealised losses of R0,1 billion on the translation of monetary assets and liabilities, and valuation of financial instruments and derivative contracts compared to unrealised gains of R2,7 billion in the prior period.</li>
</ul>
As a result of the above, basic earnings per share (EPS) decreased by 52% to R7,22 per share and Headline earnings per share (HEPS) decreased by 31% to R14,13 per share compared to the prior period.
Cash generated by operating activities increased by 20% to R17,6 billion compared to the prior period mainly due to changes in working capital. Capital expenditure, excluding movement in capital project related payables, amounted to R15,0 billion, 6% lower than the prior period.
At 31 December 2024, our total debt was R116,9 billion (US$6,2 billion) compared to R117,7&nbsp;billion (US$6,5 billion) at 30 June 2024. Sasol deposited R5,4 billion (US$0,3 billion) on the Revolving credit facility during the current period. Our net debt (excluding leases) was R81,8&nbsp;billion (US$4,3 billion) compared to R73,7 billion (US$4,1 billion) at 30 June 2024 with the increase due to the aforementioned negative free cash flow.

Earnings

Sasol Ltd Reported Revenue Decline Of 10% In 6 Months Ended Dec 31, 2024, Adj EPS Decline Of 31%

Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) senior executive Lars Moravy said in an interview published on Sunday that the company is indeed working with Elon Musk&#8216;s rocket manufacturing company SpaceX for its upcoming Roadster vehicle.
What Happened: Moravy, in an interview with Ryan McCaffrey recorded on Feb.13 and published on Sunday, said that the company is indeed working with SpaceX for the upcoming Roadster and that the company convened a meeting about the Roadster merely two days before the interview.
&#8220;Oh it is definitely real,&#8221; Moravy said in response to the rising doubts among enthusiasts about the upcoming Roadster. 
&#8220;We&#8217;re working with SpaceX on that now&#8230;. Cold gas thrusters are super cool and they add a certain level of, you know, breaking the laws of motor physics,&#8221; Moravy said.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-4-3 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Episode 499: Special Guest: Tesla Engineering VP Lars Moravy" width="500" height="375" src="https://www.youtube.com/embed/VPFgMHvSkMg?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Tesla intends to start production of the new Roadster in 2025. The sports car will be a tribute to Tesla&#8217;s first EV – the limited-production original Roadster produced by the company between 2008 and 2012.
Why It Matters: The new generation Roadster prototype was showcased at the end of the event dedicated to unveiling the Tesla Semi on November 16, 2017. Tesla then said the vehicle would be available starting in 2020 and priced around $200,000.
However, the production timeline for the vehicle has been pushed several times since.
In February 2024, Musk said that the upcoming Tesla Roadster can accelerate from&nbsp;<a href="https://www.benzinga.com/news/24/05/38817313/tesla-ceo-elon-musk-says-making-new-roadster-only-as-fast-as-model-s-plaid-would-be-ridiculous" target="_blank" rel="noreferrer noopener">0 to 60 mph in less than 1 second</a>, lower than the company's initial estimate of 1.9 seconds. The vehicle relies on a collaboration between Musk's two companies- Tesla and rocket manufacturer SpaceX- to provide the incredible performance, he added.
Tesla&#8217;s Model S Plaid, its fastest vehicle in production, can accelerate to 60 mph only in about 2 seconds. 
Musk has previously warned that the upcoming Roadster will not move Tesla's financials in a big way.
&#8220;Financially, it&#8217;s sort of a small potato situation. It&#8217;s not going to move the needle in a major way financially. It&#8217;s not even the icing on the cake but the cherry on the icing on the cake,&#8221; Musk said about the Roadster in an&nbsp;<a href="https://www.benzinga.com/news/23/05/32589810/wen-tesla-roadster-elon-musk-has-an-update-for-you" target="_blank" rel="noreferrer noopener">interview with</a>&nbsp;Ford&nbsp;CEO&nbsp;Jim Farley&nbsp;in May 2023.
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43905539/elon-musk-led-spacex-to-undertake-starships-8th-test-flight-on-friday" target="_blank" rel="noreferrer noopener">Elon Musk's SpaceX To Undertake Starship's 8th Test Flight On Friday</a></li>
</ul>
Image via Shutterstock

SPACE

Tech

TSLA

Tesla Exec Confirms Roadster Update Talks, Collaboration With SpaceX For Top Specs

Robert F. Kennedy Jr.&#8216;s appointment as U.S. Secretary of Health and Human Services has sparked concerns over funding for the National Institutes of Health. Analysts warn that potential cuts to this funding could lead to increased &#8220;uncertainty&#8221; in the healthcare sector, potentially impacting healthcare stocks.
What Happened: The NIH grants are &#8220;very important&#8221; sources of funding for a lot of labs out there, said Kyle Mikson, managing director and senior research analyst in <a href="https://www.buzzsprout.com/2414939/episodes/16662667">conversation</a> with Michael Graham, senior managing director and head of U.S. equity research internet analyst at Canaccord Genuity. 
Talking about RFK Jr.&#8217;s appointment Mikson said &#8220;He&#8217;s got some opposition to vaccines, to infectious disease research.&#8221; Highlighting the possible funding cuts along with caps on grants, Mikson added, "Things like that are causing uncertainty, causing, you know, stocks to decline."
Kennedy, known for his vaccine skepticism and conspiracy theories, has extended his influence globally, undermining health initiatives like vaccination and AIDS prevention, The New York Times <a href="https://www.nytimes.com/2024/11/30/world/africa/rfk-jr-kennedy-international-work-public-health-policies.html">reports</a>. Through his nonprofit, Children's Health Defense, Kennedy has <a href="https://www.benzinga.com/markets/equities/24/11/42254495/trumps-hhs-pick-rfk-jr-has-a-long-history-of-challenging-global-health-policies">disrupted public health efforts</a> in countries like Uganda and South Africa. He has also questioned the World Health Organization and its programs for fueling global health conspiracies.
The Donald Trump-led <a href="https://www.benzinga.com/general/health-care/25/01/43194764/trump-administration-halts-all-communications-from-the-centers-for-disease-control-as-bird-flu-spreads">administration</a> is trying to set caps at around 15% and 10% for some labs which is delayed due to broad opposition by many states. While this is detrimental to some NIH-funded labs, others have stated that they can function without indirect cost funding or support.
While, NIH awarded about $2.5 billion in grants in the first six weeks of 2024, this year, that number has plummeted to $1.4 billion.
See Also: <a href="https://www.benzinga.com/25/02/43906366/warren-buffetts-berkshire-boosts-bets-on-five-japanese-companies-admiration-has-consistently-grown-says-oracle-of-omaha-in-letter-to-shareholders">Warren Buffett&#8217;s Berkshire Boosts Bets On 5 Japanese Companies: Oracle Of Omaha Says Admiration &#8216;Has Consistently Grown&#8217;</a>
Why It Matters: While there isn't going to be a blanket impact of these caps on all healthcare firms, Mikson explains that companies that are academically focused are more likely to be impacted as compared to the ones with a mixed revenue base.
However, when considering investment opportunities, especially for growth-oriented companies with research-driven businesses, the impact is particularly important, Mikson explained.
According to the <a href="https://www.benzinga.com/markets/equities/25/02/43878703/institutional-investors-load-up-on-technology-and-financial-stocks-in-q4-while-reducing-positions-in-healthcare-sector-amid-political-uncertainty">13F SEC filings</a> during the fourth quarter, healthcare sectors experienced a sharp decline in investments, with allocations dropping by 1.4%. Adam Turnquist, the chief technical strategist at LPL Financial said that "The nomination of the so-called anti-vaccine Health Secretary, Robert F. Kennedy, Jr., and the potential for reduced Affordable Care Act subsidies," was also a potential trigger.
Kennedy&#8217;s appointment comes as healthcare costs rise and <a href="https://www.benzinga.com/general/health-care/25/02/43549057/deadly-bird-flu-strain-hits-dairy-cows-could-make-covid-seem-like-a-walk-in-the-park-expert-says">bird flu spreads</a>, raising pandemic concerns. A longtime vaccine skeptic, his stance could impact pharmaceutical companies like Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) and Moderna Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), especially as he has questioned the safety and efficacy of bird flu vaccines.
Here is a list of healthcare sector-linked exchange-traded funds, that investors could consider while trying to gain exposure to the sector.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>ETF Name</td>
<td>YTD Performance</td>
<td>One Year Performance</td>
</tr>
<tr>
<td>Health Care Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>6.41%</td>
<td>-0.46%</td>
</tr>
<tr>
<td>Vanguard Health Care ETF VHT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VHT#NYSE">VHT</a>)</td>
<td>5.79%</td>
<td>-0.19%</td>
</tr>
<tr>
<td>iShares Biotechnology ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBB#NASDAQ">IBB</a>)</td>
<td>4.51%</td>
<td>-0.18%</td>
</tr>
<tr>
<td>SPDR S&amp;P Biotech ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XBI#NYSE">XBI</a>)</td>
<td>0.19%</td>
<td>-5.79%</td>
</tr>
<tr>
<td>iShares U.S. Medical Devices ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHI#NYSE">IHI</a>)</td>
<td>10.36%</td>
<td>12.22%</td>
</tr>
<tr>
<td>iShares Global Healthcare ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IXJ#NYSE">IXJ</a>)</td>
<td>6.67%</td>
<td>-0.57%</td>
</tr>
<tr>
<td>iShares U.S. Healthcare ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IYH#NYSE">IYH</a>)</td>
<td>5.52%</td>
<td>-0.26%</td>
</tr>
<tr>
<td>Fidelity MSCI Health Care Index ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FHLC#NYSE">FHLC</a>)</td>
<td>5.90%</td>
<td>-0.27%</td>
</tr>
<tr>
<td>ARK Genomic Revolution ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>)</td>
<td>10.14%</td>
<td>-14.26%</td>
</tr>
<tr>
<td>First Trust NYSE Arca Biotechnology Index Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FBT#NYSE">FBT</a>)</td>
<td>6.72%</td>
<td>16.97%</td>
</tr>
</tbody>
</table>
</figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/02/43878703/institutional-investors-load-up-on-technology-and-financial-stocks-in-q4-while-reducing-positions-in-healthcare-sector-amid-political-uncertainty">Institutional Investors Load Up On Technology And Financial Stocks In Q4 While Reducing Positions In Healthcare Sector Amid Political Uncertainty</a></li>
</ul>
Image Via Shutterstock

Analyst Color

Equities

Government

Market Summary

Regulations

ETFs

General

ARKG

First Trust NYSE Arca Biotechnology Index Fund

FHLC

iShares Dow Jones US Medical Devices Index Fund

iShares Trust S&P Global Healthcare Sector Index Fund

iShares Trust Dow Jones US Healthcare Sector Index Fund

MRNA

NIH Funding Cuts To Spook Healthcare Stocks? RFK Jr's Confirmation At HHS Sparks Concerns Over Research Dollars, 'Causing Uncertainty,' Says Analyst

Macro Economic Events

Econ #s

Economics

Eurozone Consumer Price Index (YoY) For January 2.5% Vs. 2.5% Est.; 2.4% Prior

Eurozone Consumer Price Index (MoM) For January -0.3% Vs. -0.3% Est.; 0.4% Prior

Eurozone Core Consumer Price Index (YoY) For January 2.7% Vs. 2.7% Est.; 2.7% Prior

The Department of Government Efficiency (DOGE), overseen by Tesla CEO Elon Musk, has been found to overstate its savings from federal spending cuts.
What Happened: The DOGE, which has been promoting cuts amounting to $55 billion, primarily from canceled DEI and climate contracts, might not be as successful as it says, <a href="https://www.wsj.com/politics/policy/elon-musk-doge-federal-savings-claims-783b9507">according</a> to The Wall Street Journal. 
The WSJ analysis of government contract data provided by Deltek, a government contracting expert and data provider, indicates that the actual savings may be much lower, potentially around $2.6 billion over the next year if spending levels remain unchanged. Only about 2% of the funds would have gone to DEI-related contracts.
White House did not immediately respond to <a href="http://pro.benzinga.com">Benzinga&#8217;s</a> request for comment.
Research-focused agencies, including the Education Department and the Department of Health and Human Services, were the primary targets of these budget cuts. DOGE canceled contracts valued at over $900 million last year, affecting more than 60 agreements with the Department of Health and Human Services.
Notably, government contracts involving over 500 companies have been published on the DOGE website. It states that the defense engineering company Leidos had its contract for supporting the Social Security Administration's technology canceled.DOGE stated that this could result in savings of approximately $230 million. However, Leidos clarified, &#8221;&nbsp;"Our work supporting the Social Security Administration, and the millions of Americans it serves, is on contract and ongoing.&#8221;
Although DOGE says its estimates are conservative, experts told the WSJ that the total savings displayed on its site are likely overstated. More than a quarter of the contracts listed by DOGE had already been paid, leading to no real savings.
SEE ALSO: <a href="https://www.benzinga.com/tech/25/02/43906182/tesla-begins-hiring-for-cybercab-manufacturing-as-elon-musk-led-ev-giant-prepares-for-robotaxi-rollout">Tesla Begins Hiring For Cybercab Manufacturing As Elon Musk-Led EV Giant Prepares For Robotaxi Rollout</a>
Why It Matters: These findings come in the wake of previous controversies surrounding DOGE. Last week, DOGE faced criticism when its website, which was supposed to host all departmental updates, was found to be&nbsp;<a href="https://www.benzinga.com/news/25/02/43801493/this-says-it-all-says-mark-cuban-as-doge-website-was-still-blank-despite-musks-claim-that-all-department-actions-were-posted-there">completely blank</a>. Mark Cuban, a longtime advocate for reducing government size and enhancing efficiency, criticized Musk on social media because of this, stating, "This says it all."
Furthermore, the &#8216;DOGE dividend&#8217;, endorsed by President Donald Trump and Elon Musk, which proposes to return 20% of the savings from DOGE initiatives to American citizens has raised eyebrows. &nbsp;Erica York, Vice President of federal tax policy at the Tax Foundation, cautioned that <a href="https://www.benzinga.com/25/02/43839658/trumps-20-doge-dividend-tax-refund-plan-might-cripple-entire-effort-says-tax-expert">spending the savings</a> would "reduce the effectiveness of the entire effort." Meanwhile, Jessica Riedl, Senior Fellow at the&nbsp;Manhattan Institute, posted on X that with nearly $2 billion in budget deficit estimated $4 billion in DOGE savings would translate to just $2.42 per person if evenly distributed.
<ul>
<li>READ MORE: <a href="https://www.benzinga.com/25/02/43806208/elon-musks-doge-reports-nearly-47t-untraceable-in-federal-payments-makes-tas-tag-mandatory">Elon Musk&#8217;s DOGE Reports Nearly $4.7 Trillion Untraceable In Federal Payments, Makes TAS Tag Mandatory</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Politics

Elon Musk's DOGE Savings Of $55 Billion May Be Overstated — WSJ Analysis Reveals The Likely Actual Figure

SOPHiA GENETICS enables institutions across the globe to launch world-class oncology testing

SOPH

SOPHiA GENETICS' MSK-ACCESS Gains Global Adoption, Enabling World-Class Oncology Testing At Leading Centers

Cellectis (the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLLS#NASDAQ">CLLS</a>), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, showcases an innovative strategy for T cell engineering that leverages the pro-inflammatory properties of interleukin 2 (IL-2) with the objective to enhance CAR T cell efficacy against solid tumors, at the American Association for Cancer Research – Immuno-oncology (AACR-IO), taking place on February 23-26, 2025 in Los Angeles, CA.

CLLS

Cellectis Showcases New CAR T Cell Strategy to Fight Solid Tumors at AACR-IO

Germany Ifo Business Climate Index For February 85.2 Vs. 85.9 Est.; 85.2 (Revised) Prior

Germany Current Assessment For February 85.0 Vs. 86.5 Est.; 86.0 (Revised) Prior

Germany Business Expectations For February 85.4 Vs. 85.2 Est.; 84.3 (Revised) Prior

Sunlands Technology Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STG#NYSE">STG</a>) ("Sunlands" or the "Company"), a leader in China's adult online education market and China's adult personal interest learning market, today announced the full integration of DeepSeek, an advanced artificial intelligence (AI) model, into its operations. This marks a new phase in the company's technological transformation in the adult education sector. By leveraging DeepSeek's powerful reasoning capabilities and efficient learning mechanisms, Sunlands aims to drive innovation, empower core business functions, and optimize processes in key areas such as teaching and research, customer acquisition, and operational management, ultimately strengthening its leadership position in the industry.

Sunlands Integrates DeepSeek AI, Enhancing Adult Online Education in China

President Donald Trump reportedly issued a stringent warning to pharmaceutical companies, advising them to repatriate their manufacturing to the U.S. or face the possibility of tariffs.
What Happened: During a confidential meeting, Trump alerted drug companies about the impending tariffs, urging them to hasten the transfer of their overseas production to the U.S., reported <a href="https://www.bloomberg.com/news/articles/2025-02-21/trump-told-drugmakers-to-move-production-to-us-or-face-tariffs">Bloomberg</a> on Friday.
On Thursday, the CEO of Eli Lilly &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) David Ricks, CEO of Merck &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) Robert Davis, CEO OF Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) Albert Bourla, and Stephen Ubl, head of the industry&#8217;s largest lobbying group met Trump at the White House. The executives aimed to persuade Trump to back efforts to limit a law permitting the federal government to negotiate specific drug prices and to support measures targeting middlemen whom the industry holds responsible for increasing out-of-pocket costs.
As per the Bloomberg report, Trump did not assure to advocate with Congress to alleviate a drug pricing program established under former President Joe Biden&#8216;s tenure, a relief that the pharmaceutical sector has been seeking.
Medicare officials confirmed on Friday that the next phase of the drug pricing negotiation program&nbsp;is due and would include Novo Nordisk&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) blockbuster weight loss drugs, Ozempic and Wegovy. 
Meanwhile, Trump stated that Health and Human Services Secretary Robert F. Kennedy Jr. and his nominee for leading Medicare and Medicaid, Mehmet Oz, are working to reduce drug prices.
SEE ALSO: <a href="https://www.benzinga.com/analyst-ratings/price-target/25/02/43904842/dominos-gears-up-for-q4-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts">Domino&#8217;s Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a>
Why It Matters: Last week, Trump proposed to <a href="https://www.benzinga.com/25/02/43805852/trump-shakes-global-trade-with-25-auto-chip-and-pharma-tariffs-announcement-asian-stocks-pare-their-five-day-rally">impose a 25% tariff </a>on pharmaceuticals imported to the U.S. This latest move by Trump is not surprising given his previous confrontations with the pharmaceutical industry. During his first term, he even accused them at one point of &#8220;getting away with murder&#8221; with their drug pricing. 
ING Bank estimates that the U.S. imported nearly 36% of the drugs in 2024 with Ireland, Germany, and Switzerland being the top importers. Meanwhile, data from the Atlantic Council shows that U.S. imports of Chinese drugs surged 485% between 2020-2022.&nbsp;Following Trump&#8217;s latest warning to drugmakers to shift production in the U.S., Chinese biotech shares have taken a hit during their Asian trading session today. Shares of WuXi Biologics (OTC:<a class="ticker" href="https://www.benzinga.com/stock/WXXWY#OTC">WXXWY</a>), WuXi AppTec (OTC:<a class="ticker" href="https://www.benzinga.com/stock/WUXAY#OTC">WUXAY</a>) and Pharmaron Beijing (OTC:<a class="ticker" href="https://www.benzinga.com/stock/PHBBF#OTC">PHBBF</a>) witnessed significant declines. 
That being said, ING asserted that Trump&#8217;s call for expanding U.S. pharmaceutical manufacturing is justified, as a report from the Biden administration had indicated that capacity restrictions were the cause of drug shortages. However, a 2022 report by Washington University&nbsp;revealed that the capacity expansion would take between two to three years. 
<ul>
<li>READ MORE: <a href="https://www.benzinga.com/news/25/02/43901182/bernie-sanders-warns-if-elon-musk-can-fire-hundreds-of-thousands-of-federal-employees-imagine-what-hell-do-to-private-sector-workers">Bernie Sanders Warns: If Elon Musk Can Fire Hundreds Of Thousands Of Federal Employees, Imagine What He&#8217;ll Do To Private Sector Workers</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

PHBBF

WUXAY

WXXWY

Trump Reportedly Warns Big Pharma: Move Manufacturing To US Or Face Tariffs

Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) is reportedly preparing to launch new 13-inch and 15-inch MacBook Air models featuring <a href="https://in.benzinga.com/tech/25/02/43428732/apples-spring-2025-lineup-iphone-se-4-m4-macbook-air-and-more-expected-soon">M4 chips in March</a>.
What Happened: In his latest installment of the "Power On" newsletter, Bloomberg columnist Mark Gurman said that Apple has begun drawing down inventory of existing MacBook Air models in stores—an indication that new models are imminent.
The company has also begun readying its marketing, sales, and retail teams for the release.
While an earlier rumor suggested the M4 MacBook Air would be <a href="https://www.benzinga.com/24/12/42665141/top-apple-analyst-says-new-m4-macbook-air-could-be-available-sooner-than-expected">Apple's first hardware</a> launch of 2025, that title went to the iPhone 16e, <a href="https://in.benzinga.com/tech/25/02/43820197/apple-unveils-iphone-16e-with-a18-chip-ai-features-599-price-tag">which debuted last week</a>.
Subscribe to the&nbsp;<a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a>&nbsp;to get all the latest tech developments delivered to your inbox.
Still, Gurman maintains that Apple will introduce the new MacBook Air lineup by March "at the latest," though the exact date remains unclear.
Why It Matters: Last month, Apple reported fiscal <a href="https://in.benzinga.com/news/earnings/25/01/43355688/apple-q1-earnings-revenue-beat-eps-beat-iphone-sales-slip-installed-base-climbs-to-all-time-high-our-best-quarter-ever">first-quarter revenue</a> of $124.3 billion, surpassing analyst expectations of $124.13 billion.
The tech giant posted adjusted earnings of $2.40 per share for the quarter, exceeding the projected $2.36 per share.
Mac revenue came in at $8.99 billion, an increase from $7.78 billion in the same period last year.
Price Action: In after-hours trading, Apple declined by 0.19%, settling at $245.08 at the time of publication, according to <a href="http://pro.benzinga.com/">Benzinga Pro</a>.
Check out more of Benzinga's Consumer Tech coverage by&nbsp;<a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43905357/apple-and-google-team-up-ios-184-leak-suggests-gemini-ai-could-soon-power-siris-smarter-responses">Apple May Soon Integrate Google&#8217;s Gemini In Siri, Shows iOS 18.4 Leak</a></li>
</ul>
Disclaimer: This content was partially produced with the help of <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a> and was reviewed and published by Benzinga editors.
Image via Shutterstock

Comments

AlphaTime Acq

AlphaTime Acq (ATMC) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga